Published in Jpn J Clin Oncol on August 16, 2010
Oral anticancer drugs: how limited dosing options and dose reductions may affect outcomes in comparative trials and efficacy in patients. J Clin Oncol (2014) 1.67
Prognostic factors for survival in 1059 patients treated with sunitinib for metastatic renal cell carcinoma. Br J Cancer (2013) 1.24
Treatment outcome and prognostic factors in renal cell cancer patients with bone metastasis. Clin Exp Metastasis (2011) 0.99
Long-term Safety of Sunitinib in Metastatic Renal Cell Carcinoma. Eur Urol (2015) 0.92
Anti-VEGF therapy in mRCC: differences between Asian and non-Asian patients. Br J Cancer (2014) 0.91
Phase II study of sunitinib in Japanese patients with unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumor. Invest New Drugs (2012) 0.86
Axitinib versus sorafenib as a second-line therapy in Asian patients with metastatic renal cell carcinoma: results from a randomized registrational study. Onco Targets Ther (2015) 0.84
Real-world use of sunitinib in Japanese patients with advanced renal cell carcinoma: efficacy, safety and biomarker analyses in 1689 consecutive patients. Jpn J Clin Oncol (2015) 0.84
Sunitinib adverse events in metastatic renal cell carcinoma: a meta-analysis. Int J Clin Oncol (2012) 0.83
Sunitinib-induced severe toxicities in a Japanese patient with the ABCG2 421 AA genotype. BMC Cancer (2014) 0.82
Prognostic significance of C-reactive protein in patients with intermediate-risk metastatic renal cell carcinoma treated with molecular targeted therapy. Oncol Lett (2014) 0.82
Axitinib plasma pharmacokinetics and ethnic differences. Invest New Drugs (2015) 0.80
Congestive heart failure risk in cancer patients treated with vascular endothelial growth factor tyrosine kinase inhibitors: a systematic review and meta-analysis of 36 clinical trials. Br J Clin Pharmacol (2014) 0.80
Prognosis of Japanese patients with previously untreated metastatic renal cell carcinoma in the era of molecular-targeted therapy. Cancer Sci (2015) 0.80
Feasibly of axitinib as first-line therapy for advanced or metastatic renal cell carcinoma: a single-institution experience in Japan. BMC Urol (2015) 0.80
Validation of the Japanese version of HFS-14, a disease-specific quality of life scale for patients suffering from hand-foot syndrome. Support Care Cancer (2015) 0.78
Clinical outcome of advanced and metastatic renal cell carcinoma treated with targeted therapy: is there a difference between young and old patients? Onco Targets Ther (2014) 0.78
Safety, efficacy and prognostic analyses of sunitinib in the post-marketing surveillance study of Japanese patients with gastrointestinal stromal tumor. Jpn J Clin Oncol (2015) 0.77
Efficacy and Safety of Sorafenib Therapy on Metastatic Renal Cell Carcinoma in Korean Patients: Results from a Retrospective Multicenter Study. PLoS One (2015) 0.77
Treatment of metastatic renal cell carcinoma and renal pelvic cancer. Clin Exp Nephrol (2011) 0.77
Efficacy of a protocol including heparin ointment for treatment of multikinase inhibitor-induced hand-foot skin reactions. Support Care Cancer (2012) 0.76
Mutations in the Mitochondrial ND1 Gene Are Associated with Postoperative Prognosis of Localized Renal Cell Carcinoma. Int J Mol Sci (2016) 0.75
Sunitinib: Ten Years of Successful Clinical Use and Study in Advanced Renal Cell Carcinoma. Oncologist (2016) 0.75
Key predictive factors for efficacy of axitinib in first-line metastatic renal cell carcinoma: subgroup analysis in Japanese patients from a randomized, double-blind phase II study. Jpn J Clin Oncol (2016) 0.75
Overall survival and final efficacy and safety results from a Japanese phase II study of axitinib in cytokine-refractory metastatic renal cell carcinoma. Cancer Sci (2014) 0.75
Evaluation of response from axitinib per Response Evaluation Criteria in Solid Tumors versus Choi criteria in previously treated patients with metastatic renal cell carcinoma. Onco Targets Ther (2016) 0.75
Characteristics of early-onset hematotoxicity of sunitinib in Japanese patients with renal cell carcinoma. BMC Cancer (2017) 0.75
Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet (2011) 12.13
Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med (2013) 10.74
Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med (2012) 5.44
Human MUC1 carcinoma-associated protein confers resistance to genotoxic anticancer agents. Cancer Cell (2004) 3.55
Laparoscopic radical nephroureterectomy: a multicenter analysis in Japan. Eur Urol (2009) 2.97
Combined androgen blockade with bicalutamide for advanced prostate cancer: long-term follow-up of a phase 3, double-blind, randomized study for survival. Cancer (2009) 2.64
Survival and prognostic classification of patients with metastatic renal cell carcinoma of bone. Eur Urol (2006) 2.34
Nrf2 is essential for the chemopreventive efficacy of oltipraz against urinary bladder carcinogenesis. Cancer Res (2004) 2.23
Prognostic impact of young age on stage IV prostate cancer treated with primary androgen deprivation therapy. Int J Urol (2014) 2.21
Increased myeloid cell responses to M-CSF and RANKL cause bone loss and inflammation in SH3BP2 "cherubism" mice. Cell (2007) 2.18
Expression and functional role of β3 -adrenoceptors in the human ureter. Int J Urol (2013) 2.13
Impact of hyponatremia on survival of patients with metastatic renal cell carcinoma treated with molecular targeted therapy. Int J Urol (2012) 2.13
Prospective cohort study of the risk of prostate cancer among rotating-shift workers: findings from the Japan collaborative cohort study. Am J Epidemiol (2006) 2.11
Inhibition of mTORC2 but not mTORC1 up-regulates E-cadherin expression and inhibits cell motility by blocking HIF-2α expression in human renal cell carcinoma. J Urol (2012) 2.08
Laparoendoscopic single-site urological surgery: initial experience in Japan. Int J Urol (2010) 2.05
Long-term outcome of hand-assisted laparoscopic radical nephrectomy for T1 renal cell carcinoma. Int J Urol (2014) 2.03
Laparoscopic simultaneous bilateral adrenalectomy for testosterone-secreting bilateral adrenal tumors. Int J Urol (2013) 2.03
Prognosis of Japanese metastatic renal cell carcinoma patients in the cytokine era: a cooperative group report of 1463 patients. Eur Urol (2009) 2.03
Efficacy of traditional and alternative sunitinib treatment schedules in Japanese patients with metastatic renal cell carcinoma. Int J Urol (2014) 2.02
Feasibility of insertion/implantation of 2.0-mm-diameter gold internal fiducial markers for precise setup and real-time tumor tracking in radiotherapy. Int J Radiat Oncol Biol Phys (2003) 2.00
Efficacy of the third-generation bisphosphonate, zoledronic acid alone and combined with anti-cancer agents against small cell lung cancer cell lines. Lung Cancer (2005) 1.95
A review of current guidelines and best practice recommendations for the management of nonmuscle invasive bladder cancer by the International Bladder Cancer Group. J Urol (2011) 1.84
Collecting duct (Bellini duct) renal cell carcinoma: a nationwide survey in Japan. J Urol (2006) 1.78
Impact of multimodal treatment on survival in patients with metastatic urothelial cancer. Eur Urol (2007) 1.77
Proton magnetic resonance spectroscopy can detect creatine depletion associated with the progression of heart failure in cardiomyopathy. J Am Coll Cardiol (2003) 1.77
Enucleation of human erythroblasts involves non-muscle myosin IIB. Blood (2011) 1.76
Adenoviral gene therapy for renal cancer requires retargeting to alternative cellular receptors. Cancer Res (2002) 1.74
Downregulation of Smac/DIABLO expression in renal cell carcinoma and its prognostic significance. J Clin Oncol (2004) 1.73
Molecular features of the transition from prostatic intraepithelial neoplasia (PIN) to prostate cancer: genome-wide gene-expression profiles of prostate cancers and PINs. Cancer Res (2004) 1.73
A randomized phase II trial of personalized peptide vaccine plus low dose estramustine phosphate (EMP) versus standard dose EMP in patients with castration resistant prostate cancer. Cancer Immunol Immunother (2010) 1.70
NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia. Blood (2005) 1.67
ZD1839 (Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase. Cancer Res (2002) 1.67
Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma. Am J Respir Crit Care Med (2010) 1.66
Predicting response to methotrexate, vinblastine, doxorubicin, and cisplatin neoadjuvant chemotherapy for bladder cancers through genome-wide gene expression profiling. Clin Cancer Res (2005) 1.66
Comparisons of percent equol producers between prostate cancer patients and controls: case-controlled studies of isoflavones in Japanese, Korean and American residents. Jpn J Clin Oncol (2004) 1.65
Laparoscopy and intersex: report of 5 cases of male pseudohermaphroditism. J Med Invest (2008) 1.65
Prognostic impact of C-reactive protein for determining overall survival of patients with castration-resistant prostate cancer treated with docetaxel. Urology (2011) 1.63
Three-dimensional intrafractional movement of prostate measured during real-time tumor-tracking radiotherapy in supine and prone treatment positions. Int J Radiat Oncol Biol Phys (2002) 1.63
Curli fibers are required for development of biofilm architecture in Escherichia coli K-12 and enhance bacterial adherence to human uroepithelial cells. Microbiol Immunol (2005) 1.61
Molecular features of hormone-refractory prostate cancer cells by genome-wide gene expression profiles. Cancer Res (2007) 1.61
A molecular classification of papillary renal cell carcinoma. Cancer Res (2005) 1.60
Marked prevention of tumor growth and metastasis by a novel immunosuppressive agent, FTY720, in mouse breast cancer models. Cancer Res (2002) 1.59
Alteration in copy numbers of genes as a mechanism for acquired drug resistance. Cancer Res (2004) 1.58
Phase II study to investigate the efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma. Jpn J Clin Oncol (2007) 1.58
An alkoxide-directed intermolecular [2+2+1] annulation: a three-component coupling reaction for the synthesis of tetrasubstituted alpha,beta-unsaturated gamma-lactams. Angew Chem Int Ed Engl (2007) 1.57
Multicenter phase II trial of S-1 in patients with cytokine-refractory metastatic renal cell carcinoma. J Clin Oncol (2010) 1.57
Weekly paclitaxel and carboplatin against advanced transitional cell cancer after failure of a platinum-based regimen. Eur Urol (2007) 1.56
Perioperative management of transurethral surgery for benign prostatic hyperplasia: a nationwide survey in Japan. Int J Urol (2011) 1.55
Japanese Urological Association guidelines on prostate-specific antigen-based screening for prostate cancer and the ongoing cluster cohort study in Japan. Int J Urol (2008) 1.55
The role of lymph-node dissection in the treatment of upper urinary tract cancer: a multi-institutional study. BJU Int (2008) 1.53
Nicardipine vs. saline injection as treatment for Peyronie's disease: a prospective, randomized, single-blind trial. J Sex Med (2010) 1.53
Sorafenib rechallenge in patients with metastatic renal cell carcinoma. BJU Int (2012) 1.52
Maintenance intravesical bacillus Calmette-Guérin instillation for Ta, T1 cancer and carcinoma in situ of the bladder: randomized controlled trial by the BCG Tokyo Strain Study Group. Int J Urol (2010) 1.51
Proteasome inhibitor MG132 induces death receptor 5 through CCAAT/enhancer-binding protein homologous protein. Cancer Res (2005) 1.51
Cytogenetic abnormalities of tumor-associated endothelial cells in human malignant tumors. Am J Pathol (2009) 1.51
Identification of a novel biomarker gene set with sensitivity and specificity for distinguishing between allograft rejection and tolerance. Liver Transpl (2012) 1.49
Post-transplant lymphoproliferative disorder following renal transplantation: a single-center experience over 40 years. Int J Urol (2009) 1.48
Robust classification of renal cell carcinoma based on gene expression data and predicted cytogenetic profiles. Cancer Res (2004) 1.47
Carbamylated erythropoietin ameliorates cyclosporine nephropathy without stimulating erythropoiesis. Cell Transplant (2012) 1.47
A phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma: insights into the treatment, efficacy and safety. Jpn J Clin Oncol (2009) 1.47
Resistive index as risk factor for acute urinary retention in patients with benign prostatic hyperplasia. Urology (2010) 1.46
Health related quality of life for monosymptomatic enuretic children and their mothers. J Urol (2012) 1.46
Pattern of intravesical recurrence after surgical treatment for urothelial cancer of the upper urinary tract: a single institutional retrospective long-term follow-up study. Int J Urol (2010) 1.45
Juxtaglomerular cell tumor that was preoperatively diagnosed using selective renal venous sampling. Intern Med (2013) 1.44
A single nucleotide polymorphism within the novel sex-linked testis-specific retrotransposed PGAM4 gene influences human male fertility. PLoS One (2012) 1.44
Do testosterone levels have prognostic significance in patients with metastatic prostate cancer treated with combined androgen blockade? Int J Urol (2014) 1.44
The growth-inhibitory effects of dexamethasone on renal cell carcinoma in vivo and in vitro. Cancer Invest (2008) 1.44
A case-control study of diet and prostate cancer in Japan: possible protective effect of traditional Japanese diet. Cancer Sci (2004) 1.44
Survey of overactive bladder symptoms influencing bother before and after treatment with tamsulosin hydrochloride in Japanese patients with benign prostatic hyperplasia. Urology (2011) 1.43
Enhanced excitability of nociceptive trigeminal ganglion neurons by satellite glial cytokine following peripheral inflammation. Pain (2006) 1.43
Effect of tamsulosin on bladder blood flow and bladder function in a rat model of bladder over distention/emptying induced bladder overactivity. J Urol (2011) 1.43
Carvedilol protects tubular epithelial cells from ischemia-reperfusion injury by inhibiting oxidative stress. Int J Urol (2010) 1.43
Adipose tissue-derived stem cells suppress acute cellular rejection by TSG-6 and CD44 interaction in rat kidney transplantation. Transplantation (2014) 1.43
RENAL nephrometry score is a predictive factor for the annual growth rate of renal mass. Int J Urol (2014) 1.43